Reveal-Dx

RevealDx is a Seattle-based software company focused on improving lung cancer outcomes through advanced AI-enabled decision-support software. The company's primary product, RevealAI-Lung, is a CE-marked algorithm designed to enhance the efficiency and accuracy of lung nodule assessment. This technology aims to address limitations in lung cancer screening programs, particularly inefficient nodule detection methods and suboptimal specificity for lung cancer detection. RevealAI-Lung uses a malignancy Similarity Index (mSI) to inform clinical decision-making, potentially resulting in fewer unnecessary procedures and quicker diagnoses. Clinical studies have shown that RevealAI-Lung can achieve a 29% reduction in false positives and a 45% increase in early diagnosis. As of November 2022, RevealDx was anticipating FDA clearance for RevealAI-Lung in early 2023.

Key customers and partnerships

RevealDx has formed a significant partnership with Sirona Medical, a cloud-native radiology workflow software provider. This collaboration, first noted in 2021, integrates RevealDx's RevealAI-Lung algorithm into Sirona's unified radiology platform. The partnership aims to streamline radiologists' workflow by embedding AI deeply into clinical processes. As part of this collaboration, Hackensack Radiology Group (HRG) and Triad Radiology Associates (TRA), two leading private radiology practices in the US, have partnered to use the comprehensive solution.